Pentazocine and naloxone hydrochlorides tablets USP contain pentazocine hydrochloride USP, equivalent to 50 mg base, a member of the benzazocine series (also known as the benzomorphan series), and naloxone hydrochloride USP, equivalent to 0.5 mg base. Pentazocine and naloxone hydrochlorides tablets are an analgesic for oral administration.
|Pentazocine and naloxone hydrochlorides tablets are intended for oral use only. Severe, potentially lethal, reactions may result from misuse of pentazocine and naloxone hydrochlorides tablets by injection either alone or in combination with other substances. (See DRUG ABUSE AND DEPENDENCE section.)|
Pentazocine and naloxone hydrochlorides tablets are indicated for the relief of moderate to severe pain.
Pentazocine and naloxone hydrochlorides tablets are indicated for oral use only.
Media Articles Related to Pentazocine and Naloxone (Pentazocine / Naloxone)
American Academy of Pain Management (AAPM) 25th Annual Clinical Meeting
Source: Medscape Family Medicine Headlines [2014.09.17]
Read clinically focused news coverage of key developments from AAPM 2014.
Morphine-epilepsy drug combo can result in less pain, lower opioid doses
Source: Epilepsy News From Medical News Today [2014.09.17]
Adding a common epilepsy drug to a morphine regimen can result in better pain control with fewer side effects.
Deaths From Narcotic Painkillers Quadrupled in Past Decade: CDC
Source: MedicineNet Chronic Pain Specialty [2014.09.17]
Title: Deaths From Narcotic Painkillers Quadrupled in Past Decade: CDC
Category: Health News
Created: 9/16/2014 4:36:00 PM
Last Editorial Review: 9/17/2014 12:00:00 AM
Back-Related Leg Pain: Spine Manipulation Helps
Source: Medscape Orthopaedics Headlines [2014.09.16]
Spine manipulation plus exercise and home advice provided more short-term relief for patients with back-related leg pain than exercise and home advice alone, according to a recent study.
Medscape Medical News
Chiropractic care and exercise provide short-term relief of back-related leg pain
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2014.09.15]
In the short term, patients who received chiropractic care coupled with home exercise and advice reported greater reductions in back-related leg pain (BRLP) than those who received home exercise...
Published Studies Related to Pentazocine and Naloxone (Pentazocine / Naloxone)
Effect of acute topical application of +-pentazocine on the mechanical allodynia in diabetic mice. [2010.09.01]
Mechanical allodynia is a major complication in diabetic mellitus. Peripheral sigma(1) receptors were shown to be involved in nociceptive perception... This attenuation may be, in part, due to the normalization of increased peripheral NO contents in the hindpaw of diabetic mice.
Hazards of pentazocine for neonatal analgesia: a single-centre experience over 10 years. [2008.09]
BACKGROUND: In developing countries, neonatal analgesia for surgical procedures is a major challenge where postoperative care is inadequate. AIM: To report experience of pentazocine for neonatal surgery in a Nigerian tertiary hospital... CONCLUSION: The use of pentazocine in neonates was associated with high morbidity and mortality. Caution is required when using pentazocine for neonatal analgesia where post-operative respiratory support is insufficient.
Improvement of memory impairment by (+)- and (-)-pentazocine via sigma, but not kappa opioid receptors. [2005.09.28]
(+/-)-Pentazocine is widely used clinically to treat mild to moderate pain as a racemic compound. Although it is known that (-)-pentazocine acts as a kappa opioid receptor agonist to exhibit analgesic actions and (+)-pentazocine acts as a sigma receptor agonist without analgesic effects, their combined effect on memory has not been investigated in detail.
Clinical Trials Related to Pentazocine and Naloxone (Pentazocine / Naloxone)
Effects of Pentazocine Versus Lorazepam or Placebo on Manic Symptoms [Recruiting]
Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals.
To follow up these initial findings, we plan to conduct a larger, more rigorous,
double-blind study. We will examine whether pentazocine, an agent with kappa-opiate
activity, decreases manic symptoms.
Effects of Pentazocine on Manic Symptoms [Active, not recruiting]
The opiate neurotransmitter system is thought to be involved in many abnormal mood states.
Some researchers have suggested that changes in this system may trigger the switch to/from
manic and depressive states in bipolar disorder. One problem with most of the currently
available opiate medications is that they can produce addiction/dependence. A particular
kind of opiate medication known as kappa-opiates may be able to produce changes in this
system with much less risk of addiction. This study looks at Talwin (a combination of
pentazocine and naloxone), a medication which affects the kappa and mu opiate systems. The
study will examine whether two doses of Talwin affect manic symptoms in people who have been
admitted to the hospital. This study will give more information about the involvement of the
opiate system in bipolar disorder, and give important information for use in developing new